Skip to main content
Michael Molyneaux, MD, Family Medicine, Newport Beach, CA, Jacksonville Memorial Hospital

MichaelVanceMolyneauxMD

Family Medicine Newport Beach, CA

Chief Medical Officer, Sirnaomics, Inc.

Dr. Molyneaux is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Molyneaux's full profile

Already have an account?

Education & Training

  • Washington University
    Washington University MBA, Beta Gamma Sigma, 2010 - 2012
  • Olin Business School, Washington University
    Olin Business School, Washington UniversityMBA, 2012
  • Dalhousie University Faculty of Medicine
    Dalhousie University Faculty of MedicineClass of 1996
  • University of Prince Edward Island, Canada
    University of Prince Edward Island, CanadaBS, 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • IL State Medical License
    IL State Medical License 1998 - 2020
  • American Board of Family Medicine Family Medicine

Clinical Trials

Publications & Presentations

Journal Articles

  • Enhanced Angiogenesis and Collagen Density by Living Human Activated Leukocyte Suspension (LHALS) in a Splinted Full-Thickness Dermal Wound Model  
    Shah, V., Li, W., Molyneaux, M, Symposium On Advanced Wound Care, 1/1/2015
  • A Multicenter Randomized Dosing Trial of Spray-Applied Cell Therapy with Human Allogeneic Fibroblasts and Keratinocytes for the Treatment of Chronic Venous Leg Ulcers ...  
    Lancet, 1/1/2014
  • Biological Properties of a Living Human Activated Leukocyte Suspension (LHALS) And Its Association with Wound Healing and Tissue Remodeling  
    Shah, V., Shik, P., Li, W., Molyneaux, M., Zuloff-Shani, A., Wound Healing Society, 1/1/2014
  • Join now to see all

Press Mentions

  • Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
    Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin CancersFebruary 1st, 2023
  • Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma in Situ
    Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma in SituDecember 14th, 2022
  • Sirnaomics Will Present Clinical Study Results and Development Strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
    Sirnaomics Will Present Clinical Study Results and Development Strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China SummitMay 20th, 2022
  • Join now to see all

Hospital Affiliations